The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca
Abstract
Background: Ayahuasca is a traditional Amazon brew and its potential antidepressant properties have recently been explored in scientific settings. We conducted a double-blind placebo-controlled trial of ayahuasca with treatment-resistant depression patients ( n = 28) and healthy controls ( n = 45). Aims: We are evaluating the blood inflammatory biomarkers: C-reactive protein and interleukin 6, as a potential consequence of ayahuasca intake and their correlation with serum cortisol and brain-derived neurotrophic factor levels. Blood samples were collected at pre-treatment and 48 hours after substance ingestion to assess the concentration of inflammatory biomarkers, together with administration of the Montgomery-Åsberg Depression Rating Scale. Results: At pre-treatment, patients showed higher C-reactive protein levels than healthy controls and a significant negative correlation between C-reactive protein and serum cortisol levels was revealed ( rho = –0.40, n = 14). C-reactive protein in those patients was not correlated with Montgomery-Åsberg Depression Rating Scale scores. We observed a significant reduction of C-reactive protein levels across time in both patients and controls treated with ayahuasca, but not with placebo. Patients treated with ayahuasca showed a significant correlation ( rho = + 0.57) between larger reductions of C-reactive protein and lower depressive symptoms at 48 hours after substance ingestion (Montgomery-Åsberg Depression Rating Scale). No significant result with respect to interleukin 6 and brain-derived neurotrophic factor was found. Furthermore, these biomarkers did not predict the antidepressant response or remission rates observed. Conclusions: These findings enhance the understanding of the biological mechanisms behind the observed antidepressant effects of ayahuasca and encourage further clinical trials in adults with depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Evidence from four randomized, placebo-controlled studies investigating the acute and subacute, but not long-term effects, of a single dose of psychedelics on a molecular level show that a single treatment with ayahuasca or LSD can, but does not always, increase circulating BDNF in healthy volunteers and TRD patients (47–50) (Table 2).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [48]
In the citing paper
“Conversely, in a follow-up study, a single oral dose of ayahuasca (1 mL/kg, p.o., 0.36 mg/mL DMT, 1.86 mg/mL harmine, 0.24 mg/mL harmaline) administered to TRD patients (n = 28) and healthy controls (n = 45) in a controlled setting did not affect serum BDNF levels at 48 h after administration (48).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [48]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 1×
“Depression severity was assessed by the Hamilton Depression Scale (score >17) (Hamilton, 1960) and the Montgomery-Åsberg Depression Rating Scale (MADRS; score >18) (Montgomery and Åsberg, 1979).”
MethodA new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 1×
“Depression severity was assessed by the Hamilton Depression Scale (score >17) (Hamilton, 1960) and the Montgomery-Åsberg Depression Rating Scale (MADRS; score >18) (Montgomery and Åsberg, 1979).”
MethodInflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
Miller, A. H., Maletic, V., & Raison, C. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.029 · Cited by 3,848 · cited 2×
“We also considered possible correlations between inflammatory, BDNF, and cortisol responses to treatment, as interaction between them has been described (Gałecki and Talarowska, 2018; Miller et al., 2009) and taking into account that ayahuasca increased BDNF levels at D2 in volunteers of this trial (Almeida et al.”
BackgroundMethodThe pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212 · cited 3×
“, 2016); and (c) the activation of the IL-6 trans-signaling pathway reduces IL-6 levels in the blood (Scheller et al., 2011).”
BackgroundSlavich, G. M., & Irwin, M. R. (2014) · Psychological Bulletin · doi:10.1037/a0035302 · Cited by 2,206 · cited 15×
“Pharmacological interventions are the most used therapeutic strategy to treat major depressive disorder (MDD).”
BackgroundInfluentialGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 1×
“…interest in the use of classic serotonergic psychedelics for treatment of MDD (ayahuasca: Almeida et al., 2019; Galvão et al., 2018; Osório et al., 2015; Palhano-Fontes et al., 2015, 2018; Sanches et al., 2016; psilocybin: Carhart-Harris et al., 2016; Griffiths et al., 2016; Ross et al., 2016).”
BackgroundObesity and inflammation: the linking mechanism and the complications
Ellulu, M. S., Patimah, I., Khaza’ai, H., Rahmat, A., & Abed, Y. (2017) · Archives of Medical Science · doi:10.5114/aoms.2016.58928 · Cited by 1,982 · cited 1×
“Body mass index (BMI) was used as a co-variable in multivariable analyses due to comorbid between treatmentresistant depression and obesity, which has been associated with inflammation (Ellulu et al., 2017; Jantaratnotai et al., 2017).”
MethodRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698 · cited 14×
“, 2018), there is a renewal interest in the use of classic serotonergic psychedelics for treatment of MDD (ayahuasca: Almeida et al., 2019; Galvão et al., 2018; Osório et al., 2015; Palhano-Fontes et al., 2015, 2018; Sanches et al., 2016; psilocybin: Carhart-Harris et al., 2016; Griffiths et al., 2016; Ross et al., 20…”
BackgroundInfluentialRaison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617 · cited 2×
“The pre-treatment CRP levels observed here in patients were characterized as a low-grade inflammatory profile (CRP level >3 mg/L; healthy adult population <1 mg /L) (Macy et al., 1997; Osimo et al., 2019; Raison et al., 2013; Shine et al., 1981).”
BackgroundCarhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 1×
“…interest in the use of classic serotonergic psychedelics for treatment of MDD (ayahuasca: Almeida et al., 2019; Galvão et al., 2018; Osório et al., 2015; Palhano-Fontes et al., 2015, 2018; Sanches et al., 2016; psilocybin: Carhart-Harris et al., 2016; Griffiths et al., 2016; Ross et al., 2016).”
Background
Research works printed but not linked: 4
- Gowda S, 2009, Pan Afr Med J, 3, 17
- Köhler CA, 2018, Mol Neurobiol, 55, 4195
- Sarris J, 2018, Am J Psychiatry, 73, 575
- Sousa MBC, 2015, Psychol Stud, 20, 1
Cited by
de Vos, C. M. H., Mason, N. L., & Kuypers, K. P. C. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.724606 · Cited by 269
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Galvão-Coelho, N. L., Marx, W., Gonzalez, M., Sinclair, J., de Manincor, M., Perkins, D., & Sarris, J. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05719-1 · Cited by 137
Self-citationInflammatory signaling mechanisms in bipolar disorder
Jones, G. H., Vecera, C. M., Pinjari, O. F., & Machado‐Vieira, R. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00742-6 · Cited by 160
Kadriu, B., Greenwald, M., Henter, I. D., Gilbert, J. R., Kraus, C., Park, L. T., & Zarate, C. A. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa087 · Cited by 99
Metadata
- Authors
- Galvão-Coelho, N. L., de Menezes Galvão, A. C., de Almeida, R. N., Palhano-Fontes, F., Campos Braga, I., Lobão Soares, B., Maia-de-Oliveira, J. P., Perkins, D., Sarris, J., & de Araujo, D. B.
- Affiliations
- Department of Physiology and Behavior, Laboratory of Hormone Measurement, Federal University of Rio Grande do Norte, Natal, Brazil
- Universidade Federal do Rio Grande do Norte (BR)
- Brain Institute, Federal University of Rio Grande do Norte, Natal, Brazil
- National Science and Technology Institute for Translational Medicine, Natal, Brazil
- The University of Melbourne (AU)
- ORCID
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2020-07-10
- Volume
- 34
- Issue
- 10
- Pages
- 1125-1133
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W3023636576
- Semantic Scholar
- 26ddc50420d68a18d4f5853e948427e21b4025ad
- Cited by
- 128
- References
- 71
- Citations by year
- 2026: 13 · 2025: 13 · 2024: 22 · 2023: 31 · 2022: 23 · 2021: 20 · 2020: 6
- FWCI
- 7.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (1577/2013, 1677/2012)
- National Science and Technology Institute for Translational Medicine (Fapesp 2014/50891-1 CNPq 465458/2014-9).)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (466760/2014, 479466/2013)
- instituto nacional de ciência e tecnologia translacional em medicina
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ayahuasca, antidepressant effects, treatment-resistant depression, inflammatory markers, C-reactive protein, interleukin-6, brain-derived neurotrophic factor, serum cortisol, neuroinflammation, antidepressant response prediction
- MeSH terms
- Adult, Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Female, Humans, Inflammation, Male, Psychiatric Status Rating Scales, Biomarkers, Case-Control Studies, Treatment Outcome, Plant Preparations, Banisteriopsis, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca. https://app.cochat.ai/papers/10.1177/0269881120936486
- The paper
- Galvão-Coelho, N. L., de Menezes Galvão, A. C., de Almeida, R. N., Palhano-Fontes, F., Campos Braga, I., Lobão Soares, B., Maia-de-Oliveira, J. P., Perkins, D., Sarris, J., & de Araujo, D. B. (2020). Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca. Journal of Psychopharmacology. https://doi.org/10.1177/0269881120936486
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.